{"id":500030,"date":"2021-06-02T08:37:46","date_gmt":"2021-06-02T12:37:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-reschedules-clinical-update-conference-call-and-webcast-to-june-14-2021\/"},"modified":"2021-06-02T08:37:46","modified_gmt":"2021-06-02T12:37:46","slug":"gracell-biotechnologies-reschedules-clinical-update-conference-call-and-webcast-to-june-14-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-reschedules-clinical-update-conference-call-and-webcast-to-june-14-2021\/","title":{"rendered":"Gracell Biotechnologies Reschedules Clinical Update Conference Call and Webcast to June 14, 2021"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SUZHOU, China and PALO ALTO, Calif., June  02, 2021  (GLOBE NEWSWIRE) &#8212; Gracell Biotechnologies Inc. (NASDAQ: GRCL) (\u201cGracell\u201d), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it has rescheduled its conference call and webcast to present an update on the results of a Phase 1 first-in-human multicenter investigator-initiated study of the FasTCAR-enabled BCMA\/CD19 dual-targeting CAR-T cell therapy, GC012F, in relapsed\/refractory multiple myeloma. This data was accepted for poster presentations at the 2021 American Society of Clinical Oncology Annual Meeting and the European Hematology Association (EHA) 2021 Virtual Congress.\u00a0The conference call and webcast have been rescheduled to a time after the release of the e-poster presentation at the EHA 2021 Virtual Congress. Details for the rescheduled conference call are as follows: <\/p>\n<p align=\"justify\">\n        <strong>Conference call and webcast details:<\/strong>\n      <\/p>\n<p align=\"justify\">Monday, June 14, 2021 @ 8:00 am ET<\/p>\n<p align=\"justify\">Investor domestic dial-in: 877-407-0784<\/p>\n<p align=\"justify\">Investor international dial-in: +1 201-689-8560<\/p>\n<p align=\"justify\">Conference ID: 13719675<\/p>\n<p align=\"justify\">Live webcast link: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sikeqWSBnGe-RwECTSwOTmoK1tPg5sv7VotknEPYxWr3BXNgCskTfxl05PG25OO4Ej7vSNyA77JKTk4bjSzJ6d0QqkJPn3Xa2cEgAJblKJshFm2gR9w71-UCe95rAXqnyj0UNLA7HsH9He2Ls_B32Eoy8uC6TaSMVj70IrBFNsryqghBvPdUkbYOtXmFM2GKkCXuBJFe2b-Oz6zQdLeBkQ==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/ir.gracellbio.com\/news-events\/events-and-presentations<\/a><\/p>\n<p align=\"justify\">A replay of the webcast will be available on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=e_7lG2pXFFxSBGm4OH_X4CaWK37Zf-bTjNvQyp11ZA4__HuHncxy35yWj6xNK25zlSaIOU-_NfzIKG6iFZYB__u6kVh42k1r-w8zyzNknSs=\" rel=\"nofollow noopener\" target=\"_blank\">ir.gracellbio.com<\/a>\u00a0shortly after the conclusion of the event for 90 days.<\/p>\n<p align=\"justify\">\n        <strong>About Gracell <\/strong>\n      <\/p>\n<p align=\"justify\">Gracell Biotechnologies Inc.\u00a0(&#8220;Gracell&#8221;) is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JK5-4XBi-JM1CRNIn6hnh-L4fIG7Q3ZK4UPWiVK7u3fBLSI14HcY2hD9At0WKM8ejBmHZGLENW3yZWUkyur55ZFCTOK1vDMK1D_srIY4Ow0=\" rel=\"nofollow noopener\" target=\"_blank\">www.gracellbio.com<\/a><\/p>\n<p align=\"justify\">Follow @GracellBio on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AbiEZdznjI28GAg708i2GDfHFK85MgLd7AEoat0DuMBQewqeaJADJLrcfRqAFC-PcQOrTIK-JY9Waa3cKnugxOXFLNQ-PVOhSjU9WW2lx5M=\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a><\/p>\n<p align=\"justify\">\n        <strong>Media contact<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Marvin Tang<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BONUsJHYSs__CVJEKRnFOdFqO0Mdw7ovxK6ZRx-nUn_pxo7IG4K8qkKBLceJ4nvhNGsgSH9TM-Lr3LuN2Xudv3jzwDc-Rk3ac_EVO5UxyEyTO-A9o_OJ-2VOR5UF76Xc\" rel=\"nofollow noopener\" target=\"_blank\">marvin.tang@gracellbio.com<\/a>\n      <\/p>\n<p align=\"justify\">\n        <strong>Investor contact<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Gracie Tong<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5e4CqZ2Ge6xxpHz4RD0hwdLntihVSbcVa1EVxJyN4MukPyT5Uc784gMlFKuwK_8JkaAnm38Ae72i_fCG6dFj2ucN-sHLMFJRAGvOUiPMXp5BDlLpK8QfbX48aM-u9hif\" rel=\"nofollow noopener\" target=\"_blank\">gracie.tong@gracellbio.com<\/a>\n      <\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NzQyNiM0MjIzMjg2IzIyMDQyODY=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/78a5782e-2da4-436a-be03-f631e35417f4\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SUZHOU, China and PALO ALTO, Calif., June 02, 2021 (GLOBE NEWSWIRE) &#8212; Gracell Biotechnologies Inc. (NASDAQ: GRCL) (\u201cGracell\u201d), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it has rescheduled its conference call and webcast to present an update on the results of a Phase 1 first-in-human multicenter investigator-initiated study of the FasTCAR-enabled BCMA\/CD19 dual-targeting CAR-T cell therapy, GC012F, in relapsed\/refractory multiple myeloma. This data was accepted for poster presentations at the 2021 American Society of Clinical Oncology Annual Meeting and the European Hematology Association (EHA) 2021 Virtual Congress.\u00a0The conference call and webcast have been rescheduled to a time after the release of the e-poster &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-reschedules-clinical-update-conference-call-and-webcast-to-june-14-2021\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Gracell Biotechnologies Reschedules Clinical Update Conference Call and Webcast to June 14, 2021&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-500030","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Gracell Biotechnologies Reschedules Clinical Update Conference Call and Webcast to June 14, 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-reschedules-clinical-update-conference-call-and-webcast-to-june-14-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gracell Biotechnologies Reschedules Clinical Update Conference Call and Webcast to June 14, 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SUZHOU, China and PALO ALTO, Calif., June 02, 2021 (GLOBE NEWSWIRE) &#8212; Gracell Biotechnologies Inc. (NASDAQ: GRCL) (\u201cGracell\u201d), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it has rescheduled its conference call and webcast to present an update on the results of a Phase 1 first-in-human multicenter investigator-initiated study of the FasTCAR-enabled BCMA\/CD19 dual-targeting CAR-T cell therapy, GC012F, in relapsed\/refractory multiple myeloma. This data was accepted for poster presentations at the 2021 American Society of Clinical Oncology Annual Meeting and the European Hematology Association (EHA) 2021 Virtual Congress.\u00a0The conference call and webcast have been rescheduled to a time after the release of the e-poster &hellip; Continue reading &quot;Gracell Biotechnologies Reschedules Clinical Update Conference Call and Webcast to June 14, 2021&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-reschedules-clinical-update-conference-call-and-webcast-to-june-14-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-02T12:37:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NzQyNiM0MjIzMjg2IzIyMDQyODY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gracell-biotechnologies-reschedules-clinical-update-conference-call-and-webcast-to-june-14-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gracell-biotechnologies-reschedules-clinical-update-conference-call-and-webcast-to-june-14-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Gracell Biotechnologies Reschedules Clinical Update Conference Call and Webcast to June 14, 2021\",\"datePublished\":\"2021-06-02T12:37:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gracell-biotechnologies-reschedules-clinical-update-conference-call-and-webcast-to-june-14-2021\\\/\"},\"wordCount\":301,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gracell-biotechnologies-reschedules-clinical-update-conference-call-and-webcast-to-june-14-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NzQyNiM0MjIzMjg2IzIyMDQyODY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gracell-biotechnologies-reschedules-clinical-update-conference-call-and-webcast-to-june-14-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gracell-biotechnologies-reschedules-clinical-update-conference-call-and-webcast-to-june-14-2021\\\/\",\"name\":\"Gracell Biotechnologies Reschedules Clinical Update Conference Call and Webcast to June 14, 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gracell-biotechnologies-reschedules-clinical-update-conference-call-and-webcast-to-june-14-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gracell-biotechnologies-reschedules-clinical-update-conference-call-and-webcast-to-june-14-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NzQyNiM0MjIzMjg2IzIyMDQyODY=\",\"datePublished\":\"2021-06-02T12:37:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gracell-biotechnologies-reschedules-clinical-update-conference-call-and-webcast-to-june-14-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gracell-biotechnologies-reschedules-clinical-update-conference-call-and-webcast-to-june-14-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gracell-biotechnologies-reschedules-clinical-update-conference-call-and-webcast-to-june-14-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NzQyNiM0MjIzMjg2IzIyMDQyODY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NzQyNiM0MjIzMjg2IzIyMDQyODY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gracell-biotechnologies-reschedules-clinical-update-conference-call-and-webcast-to-june-14-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gracell Biotechnologies Reschedules Clinical Update Conference Call and Webcast to June 14, 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gracell Biotechnologies Reschedules Clinical Update Conference Call and Webcast to June 14, 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-reschedules-clinical-update-conference-call-and-webcast-to-june-14-2021\/","og_locale":"en_US","og_type":"article","og_title":"Gracell Biotechnologies Reschedules Clinical Update Conference Call and Webcast to June 14, 2021 - Market Newsdesk","og_description":"SUZHOU, China and PALO ALTO, Calif., June 02, 2021 (GLOBE NEWSWIRE) &#8212; Gracell Biotechnologies Inc. (NASDAQ: GRCL) (\u201cGracell\u201d), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it has rescheduled its conference call and webcast to present an update on the results of a Phase 1 first-in-human multicenter investigator-initiated study of the FasTCAR-enabled BCMA\/CD19 dual-targeting CAR-T cell therapy, GC012F, in relapsed\/refractory multiple myeloma. This data was accepted for poster presentations at the 2021 American Society of Clinical Oncology Annual Meeting and the European Hematology Association (EHA) 2021 Virtual Congress.\u00a0The conference call and webcast have been rescheduled to a time after the release of the e-poster &hellip; Continue reading \"Gracell Biotechnologies Reschedules Clinical Update Conference Call and Webcast to June 14, 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-reschedules-clinical-update-conference-call-and-webcast-to-june-14-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-06-02T12:37:46+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NzQyNiM0MjIzMjg2IzIyMDQyODY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-reschedules-clinical-update-conference-call-and-webcast-to-june-14-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-reschedules-clinical-update-conference-call-and-webcast-to-june-14-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Gracell Biotechnologies Reschedules Clinical Update Conference Call and Webcast to June 14, 2021","datePublished":"2021-06-02T12:37:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-reschedules-clinical-update-conference-call-and-webcast-to-june-14-2021\/"},"wordCount":301,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-reschedules-clinical-update-conference-call-and-webcast-to-june-14-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NzQyNiM0MjIzMjg2IzIyMDQyODY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-reschedules-clinical-update-conference-call-and-webcast-to-june-14-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-reschedules-clinical-update-conference-call-and-webcast-to-june-14-2021\/","name":"Gracell Biotechnologies Reschedules Clinical Update Conference Call and Webcast to June 14, 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-reschedules-clinical-update-conference-call-and-webcast-to-june-14-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-reschedules-clinical-update-conference-call-and-webcast-to-june-14-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NzQyNiM0MjIzMjg2IzIyMDQyODY=","datePublished":"2021-06-02T12:37:46+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-reschedules-clinical-update-conference-call-and-webcast-to-june-14-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-reschedules-clinical-update-conference-call-and-webcast-to-june-14-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-reschedules-clinical-update-conference-call-and-webcast-to-june-14-2021\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NzQyNiM0MjIzMjg2IzIyMDQyODY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NzQyNiM0MjIzMjg2IzIyMDQyODY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gracell-biotechnologies-reschedules-clinical-update-conference-call-and-webcast-to-june-14-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Gracell Biotechnologies Reschedules Clinical Update Conference Call and Webcast to June 14, 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/500030","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=500030"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/500030\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=500030"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=500030"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=500030"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}